We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




More Dialysis Doesn't Improve Survival of Kidney Patients

By HospiMedica staff writers
Posted on 15 Jan 2003
A large multicenter study of 1,850 patients with end-stage kidney disease (ESKD) has found that contrary to expectations, longer dialysis treatment and use of a highly permeable artificial kidney do not improve survival rates or reduce hospitalization. More...
The results were reported in the December 19, 2003, issue of The New England Journal of Medicine.

These outcomes conflict with previous studies that reported improvements in morbidity and mortality in patients treated with a higher dose of dialysis or a more permeable membrane. However, the new study did show some benefit for selected subgroups. Deaths and hospitalization from heart disease were significantly lower in those patients treated with the more permeable membrane, and the mortality rate of women receiving higher doses of dialysis was 19% lower than that of women receiving the standard dose. In about 60% of ESKD patients, the cause of death is heart disease or stroke.

"We learned a higher dose of dialysis and a higher permeable membrane are not enough,” said Dr. Robert Toto, senior author and professor of internal medicine at the University of Texas Southwestern Medical Center (Dallas, USA; www.swmed.edu). "We've got to do better. We've got to do more to help improve the quality and duration of life of patients on hemodialysis.” The UT Southwestern Medical Center was one of the participating centers in the study.




Related Links:
University of Texas Southwestern Medical Ctr

Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.